Madrigal Pharmaceuticals Inc (MDGL)
331.00
-0.32
(-0.10%)
USD |
NASDAQ |
Nov 05, 11:37
Madrigal Pharmaceuticals Enterprise Value: 6.345B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 6.345B |
| November 01, 2024 | 6.089B |
| October 31, 2024 | 4.775B |
| October 30, 2024 | 3.828B |
| October 29, 2024 | 3.869B |
| October 28, 2024 | 3.851B |
| October 25, 2024 | 3.712B |
| October 24, 2024 | 3.545B |
| October 23, 2024 | 3.534B |
| October 22, 2024 | 3.558B |
| October 21, 2024 | 3.674B |
| October 18, 2024 | 3.795B |
| October 17, 2024 | 3.708B |
| October 16, 2024 | 3.820B |
| October 15, 2024 | 3.832B |
| October 14, 2024 | 3.816B |
| October 11, 2024 | 3.788B |
| October 10, 2024 | 3.710B |
| October 09, 2024 | 3.717B |
| October 08, 2024 | 3.845B |
| October 07, 2024 | 3.803B |
| October 04, 2024 | 3.663B |
| October 03, 2024 | 3.623B |
| October 02, 2024 | 3.679B |
| October 01, 2024 | 3.683B |
| Date | Value |
|---|---|
| September 30, 2024 | 3.746B |
| September 27, 2024 | 3.671B |
| September 26, 2024 | 3.703B |
| September 25, 2024 | 3.753B |
| September 24, 2024 | 3.902B |
| September 23, 2024 | 3.960B |
| September 20, 2024 | 4.129B |
| September 19, 2024 | 4.319B |
| September 18, 2024 | 4.121B |
| September 17, 2024 | 4.126B |
| September 16, 2024 | 4.126B |
| September 13, 2024 | 4.309B |
| September 12, 2024 | 4.156B |
| September 11, 2024 | 4.118B |
| September 10, 2024 | 4.176B |
| September 09, 2024 | 4.241B |
| September 06, 2024 | 4.354B |
| September 05, 2024 | 4.400B |
| September 04, 2024 | 4.386B |
| September 03, 2024 | 4.192B |
| August 30, 2024 | 4.425B |
| August 29, 2024 | 4.459B |
| August 28, 2024 | 4.504B |
| August 27, 2024 | 4.591B |
| August 26, 2024 | 4.613B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
519.25M
Minimum
Apr 03 2020
6.345B
Maximum
Nov 04 2024
2.310B
Average
1.470B
Median
Nov 30 2020
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 1.924B |
| Sarepta Therapeutics Inc | 11.50B |
| ADMA Biologics Inc | 4.497B |
| Intra-Cellular Therapies Inc | 8.129B |
| Entrada Therapeutics Inc | 190.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.96M |
| Revenue (Quarterly) | 62.18M |
| Total Expenses (Quarterly) | 178.48M |
| EPS Diluted (Quarterly) | -4.92 |
| Gross Profit Margin (Quarterly) | 96.54% |
| Profit Margin (Quarterly) | -172.0% |
| Earnings Yield | -7.59% |
| Normalized Earnings Yield | -7.589 |